It has been reported that PARP inhibitors can promote the activation of the TP53 signaling pathway,[39] while tumor suppressor factors can inhibit cancer progression by regulating the expression of ferroptosis‐related gene or proteins. This evidence concerns the gene TP53 and cancer.